Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.88 |
| ▸ | HPGD | P15428 | 7/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.88 |
| ▸ | GAA | P10253 | 3/20 | 0.88 |
| ▸ | LMNA | P02545 | 2/20 | 0.88 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.88 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | GLA | P06280 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CCR4 | P51679 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67224 | 0.93 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4EHSD17B10GAA | |
| SCHEMBL27823419 | 0.82 | ALDH1A1 (0.65) | ALDH1A1HPGDKDM4EHSD17B10GAA | |
| SCHEMBL24426667 | 0.79 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4EHSD17B10GAA | |
| SCHEMBL5346582 | 0.79 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4EHSD17B10GAA | |
| SCHEMBL11095245 | 0.79 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4EHSD17B10GAA | |
| SCHEMBL31485737 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HPGDKDM4EHSD17B10GAA | |
| SCHEMBL17973508 | 0.75 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4EHSD17B10GAA | |
| SCHEMBL31318631 | 0.75 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4EHSD17B10GAA | |
| SCHEMBL9972728 | 0.75 | PTGS1 (0.71) | ALDH1A1HPGDKDM4EHSD17B10GAA | |
| SCHEMBL9923795 | 0.75 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4EHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106038728-B | Effective component of clematis root and preparation method and application thereof | 成都大学 | 2020-04-28 | — | — | CN | claimed |
| CN-107810918-A | A kind of cultural method of No. two chickens in Plain | 广西平南县平原农牧有限公司 | 2018-03-20 | — | — | CN | claimed |
| CN-102816933-A | Treatment process method of chrome slag | GONGXIN HUAXIN TECHNOLOGY INDUSTRY CO LTD | 2012-12-12 | — | — | CN | claimed |
| CN-102276565-A | Method for extracting and separating siderin | — | 2011-12-14 | — | — | CN | claimed |
| US-20260102484-A1 | ADJUVANTS FOR ENHANCING THE IMMUNE RESPONSE | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4599856-A1 | SCAR REDUCING WOUND CLOSURE MATERIALS | Lankenau Institute for Medical Research (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4587049-A1 | ADJUVANTS FOR ENHANCING THE IMMUNE RESPONSE | Lankenau Institute for Medical Research (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024059321-A1 | ADJUVANTS FOR ENHANCING THE IMMUNE RESPONSE | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20220176011-A1 | SCAR REDUCING WOUND CLOSURE MATERIALS | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2022-06-09 | — | — | US | disclosed |
| CN-114173801-A | Materials and methods for multidirectional biological transport | 詹森生物科技公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3927383-A1 | SCAR REDUCING WOUND CLOSURE MATERIALS | Lankenau Institute for Medical Research (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-108634364-B | Couch grass extract, preparation method thereof and application thereof in cigarettes | 河南中烟工业有限责任公司 | 2021-05-18 | — | — | CN | disclosed |
| US-6953575-B2 | Methods of treating central nervous system disorders using viral vectors | AVIGEN, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6309634-B1 | DELIVERING VIRAL VECTORS TO THE CNS ARE PROVIDED. | AVIGEN, INC. | 2001-10-30 | — | — | US | disclosed |
| WO-1998041226-A9 | PHARMACEUTICAL COMBINED PREPARATIONS CONTAINING ERYTHROPOIETIN AND IRON PREPARATIONS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-11-25 | — | — | WO | disclosed |
| EP-0851762-A1 | PHARMACEUTICAL COMBINATION PREPARATIONS CONTAINING ERYTHROPOIETIN AND IRON PREPARATIONS | Roche Diagnostics GmbH (DE) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997009996-A1 | PHARMACEUTICAL COMBINATION PREPARATIONS CONTAINING ERYTHROPOIETIN AND IRON PREPARATIONS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-03-20 | — | — | WO | disclosed |
| EP-0559691-A1 | TREATMENT OF EXERCISE-INDUCED PULMONARY HEMORRHAGE IN ANIMALS. | MILLS JOHN A (CA) | 1993-09-15 | — | — | EP | disclosed |
| WO-1988003808-A1 | METHOD FOR TREATING IRON OVERLOAD | KIRIN-AMGEN, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| EP-0269394-A2 | Method for treating iron overload | Kirin-Amgen, Inc. (US) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102484-A1 | ADJUVANTS FOR ENHANCING THE IMMUNE RESPONSE | HIF1A, HIF1AN, EGLN3 | ALDH1A1 2541/4885HPGD 305/4885KDM4E 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.